Related references
Note: Only part of the references are listed.Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
William T. Abraham et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Javed Butler et al.
EUROPEAN HEART JOURNAL (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
David D. Berg et al.
JAMA CARDIOLOGY (2021)
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M. Y. Lee et al.
CIRCULATION (2021)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
Mikhail N. Kosiborod et al.
CIRCULATION (2020)
Omics phenotyping in heart failure: the next frontier
Antoni Bayes-Genis et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Understanding the Mechanistic Benefit of Heart Failure Drugs Matters
James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program
Gemma A. Figtree et al.
CIRCULATION (2019)
Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2019)
Metabolic modulation predicts heart failure tests performance
Daniel Contaifer et al.
PLOS ONE (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
Milton Packer
CARDIOVASCULAR DIABETOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Radholm et al.
CIRCULATION (2018)
Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study
Julio Nunez et al.
CLINICAL CARDIOLOGY (2018)
EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
P3193The ketone body 3-hydroxybutyrate increases cardiac output without affecting myocardial external efficiency
R Nielsen et al.
EUROPEAN HEART JOURNAL (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients
David E. Lanfear et al.
JACC-HEART FAILURE (2017)
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Ben A. Kappel et al.
CIRCULATION (2017)
Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus
Eylem Levelt et al.
EUROPEAN HEART JOURNAL (2016)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
Evolving Concepts of Myocardial Energy Metabolism More Than Just Fats and Carbohydrates
Gary D. Lopaschuk et al.
CIRCULATION RESEARCH (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Cardiovascular Drug Development
Christopher B. Fordyce et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy
Roger M. Beadle et al.
JACC-HEART FAILURE (2015)
Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
Beshay N. Zordoky et al.
PLOS ONE (2015)
The annual global economic burden of heart failure
Christopher Cook et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Exercise Standards for Testing and Training: A Scientific Statement From the American Heart Association
Gerald F. Fletcher et al.
CIRCULATION (2013)
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
Frank P. Brouwers et al.
EUROPEAN HEART JOURNAL (2013)
Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure
Roberto Spoladore et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2013)
Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure
Kathryn E. Flynn et al.
AMERICAN HEART JOURNAL (2012)
Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction Prevalence, Therapies, and Outcomes
Benjamin A. Steinberg et al.
CIRCULATION (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Insulin Resistance and Heart Failure: Molecular Mechanisms
Annayya R. Aroor et al.
HEART FAILURE CLINICS (2012)
Mitochondria in heart failure
Mariana G. Rosca et al.
CARDIOVASCULAR RESEARCH (2010)
Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
Khalid Abozguia et al.
CIRCULATION (2010)
Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus
K. M. Goode et al.
HEART (2009)
Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy Deficiency
Thanh T. Phan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Metabolic mechanisms in heart failure
Houman Ashrafian et al.
CIRCULATION (2007)
Mechanisms of disease - The failing heart - An engine out of fuel
Stefan Neubauer
NEW ENGLAND JOURNAL OF MEDICINE (2007)
On the hypothesis that the failing heart is energy starved: Lessons learned from the metabolism of ATP and creatine
Joanne S. Ingwall
CURRENT HYPERTENSION REPORTS (2006)
Systolic and diastolic heart failure in the community
Francesca Bursi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure
Gabriele Fragasso et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure
G Fragasso et al.
EUROPEAN HEART JOURNAL (2006)
Share Paper
